Leadership: Cultivating a Culture of High CuriosityThe bar is set high for Medical Affairs (MA) talent: traditional capabilities are no longer sufficient to address Share XLeadership: Cultivating a Culture of High Curiosityhttps://pharmaphorum.com/partner-content-market-access/leadership-cultivating-a-culture-of-high-curiosity/
Novartis says $4m price is reasonable for SMA gene therapyNovartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money Share XNovartis says $4m price is reasonable for SMA gene therapyhttps://pharmaphorum.com/news/novartis-says-4m-price-is-reasonable-for-sma-gene-therapy/
Sandoz axes filing of US Rituxan biosimilarSandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved Share XSandoz axes filing of US Rituxan biosimilarhttps://pharmaphorum.com/news/sandoz-axes-filing-of-us-rituxan-biosimilar/
Pfizer and Novartis collaborate to find liver disease therapyPfizer has joined forces with Novartis to bring together the therapies they have been working on independently, to Share XPfizer and Novartis collaborate to find liver disease therapyhttps://pharmaphorum.com/news/pfizer-and-novartis-collaborate-to-find-liver-disease-therapy/
Alcon to build digital platform to improve cataract surgeryNovartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract Share XAlcon to build digital platform to improve cataract surgeryhttps://pharmaphorum.com/news/alcon-to-build-digital-platform-to-improve-cataract-surgery/
Novartis wants to blaze a trail in breast cancer with PI3K drugNovartis is preparing to file its PI3K drug combination for a certain group of breast cancer patients, after Share XNovartis wants to blaze a trail in breast cancer with PI3K drughttps://pharmaphorum.com/news/novartis-wants-to-blaze-a-trail-in-breast-cancer-with-pik3-drug/
Novartis to buy cancer drug firm Endocyte for $2.1bnNovartis has announced plans to buy cancer drug firm Endocyte for $2.1 billion cash. The Swiss pharma giant Share XNovartis to buy cancer drug firm Endocyte for $2.1bnhttps://pharmaphorum.com/news/novartis-to-buy-cancer-drug-firm-endocyte-for-2-1bn/
AZ to continue with investment freeze following ‘no deal’ BrexitAstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide Share XAZ to continue with investment freeze following ‘no deal’ Brexithttps://pharmaphorum.com/news/az-to-continue-with-investment-freeze-following-no-deal-brexit/
Novartis challenges court ruling allowing use of Avastin in wet AMDNovartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Share XNovartis challenges court ruling allowing use of Avastin in wet AMDhttps://pharmaphorum.com/news/novartis-challenges-court-ruling-allowing-use-of-avastin-in-wet-amd/
